Fralick, Michael
Jenkins, Alicia J.
Khunti, Kamlesh
Mbanya, Jean Claude
Mohan, Viswanathan http://orcid.org/0000-0001-5038-6210
Schmidt, Maria Inês
Article History
Accepted: 8 December 2021
First Online: 17 January 2022
Competing interests
: M.F. is part of a start-up company called ProofDx that has created a point-of-care testing device using CRISPR for COVID-19. M.F. has received multiple grants from CIHR and the Canadian Military for clinical trials to identify treatments for COVID-19. A.J.J. has received peer-reviewed diabetes-related grants from the following bodies: NHMRC Australia, JDRF Australia, JDRF International, Abbott Europe, Sanofi-Aventis, and Sydney Medical School and Foundation. A.J.J. is an honorary board member of Insulin for Life, a founder/co-chair of the Diabetes Advocacy Group, including members of Insulin for Life, the Life for a Child programme and Children Living as Neighbours, a member of the International Diabetes Federation (IDF) Western Pacific Executive Council, Australia’s representative to the IDF and elected to the IDF Western Pacific Executive Council. K.K. has acted as consultant, advisory board member and speaker for Abbott, Amgen, AstraZeneca, Bayer, NAPP, Lilly, Merck Sharp and Dohme, Novartis, Novo Nordisk, Roche, Berlin-Chemie AG/Menarini Group, Sanofi-Aventis, Servier and Boehringer Ingelheim, and EACME grants from Boehringer Ingelheim, AstraZeneca, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, and Merck Sharp & Dohme. J.C.M. and the institutions to which he is associated have received funding from the following pharmaceutical companies for educational, advisory and research activities: AstraZeneca, GSK, Novartis, Novo Nordisk, Sanofi and Servier. V.M. has acted as consultant and speaker and received research or educational grants from Novo Nordisk, MSD, Eli Lilly, AstraZeneca, Novartis, Boehringer Ingelheim, Lifescan J&J, Sanofi-Aventis, Roche Diagnostics, Abbott and from several Indian pharmaceutical companies including USV, Dr. Reddy’s Laboratories and Sun Pharma. M.I.S. declares no competing interests.
Free to read: This content has been made available to all.